Literature DB >> 14557625

The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Sandra Kao1, Mohammad A Khan, Eri Miyagi, Ron Plishka, Alicia Buckler-White, Klaus Strebel.   

Abstract

Replication of human immunodeficiency virus type 1 (HIV-1) in most primary cells and some immortalized T-cell lines depends on the activity of the viral infectivity factor (Vif). Vif has the ability to counteract a cellular inhibitor, recently identified as CEM15, that blocks infectivity of Vif-defective HIV-1 variants. CEM15 is identical to APOBEC3G and belongs to a family of proteins involved in RNA and DNA deamination. We cloned APOBEC3G from a human kidney cDNA library and confirmed that the protein acts as a potent inhibitor of HIV replication and is sensitive to the activity of Vif. We found that wild-type Vif inhibits packaging of APOBEC3G into virus particles in a dose-dependent manner. In contrast, biologically inactive variants carrying in-frame deletions in various regions of Vif or mutation of two highly conserved cysteine residues did not inhibit packaging of APOBEC3G. Interestingly, expression of APOBEC3G in the presence of wild-type Vif not only affected viral packaging but also reduced its intracellular expression level. This effect was not seen in the presence of biologically inactive Vif variants. Pulse-chase analyses did not reveal a significant difference in the stability of APOBEC3G in the presence or absence of Vif. However, in the presence of Vif, the rate of synthesis of APOBEC3G was slightly reduced. The reduction of intracellular APOBEC3G in the presence of Vif does not fully account for the Vif-induced reduction of virus-associated APOBEC3G, suggesting that Vif may function at several levels to prevent packaging of APOBEC3G into virus particles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557625      PMCID: PMC229358          DOI: 10.1128/jvi.77.21.11398-11407.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

Review 1.  Quality control by DNA repair.

Authors:  T Lindahl; R D Wood
Journal:  Science       Date:  1999-12-03       Impact factor: 47.728

2.  Evidence for a newly discovered cellular anti-HIV-1 phenotype.

Authors:  J H Simon; N C Gaddis; R A Fouchier; M H Malim
Journal:  Nat Med       Date:  1998-12       Impact factor: 53.440

3.  The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells.

Authors:  J H Simon; R A Fouchier; T E Southerling; C B Guerra; C K Grant; M H Malim
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Pseudotyping human immunodeficiency virus type 1 by vesicular stomatitis virus G protein does not reduce the cell-dependent requirement of vif for optimal infectivity: functional difference between Vif and Nef.

Authors:  Hirofumi Akari; Tsuneo Uchiyama; Tomoharu Fukumori; Shinya Iida; A Hajime Koyama; Akio Adachi
Journal:  J Gen Virol       Date:  1999-11       Impact factor: 3.891

5.  Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.

Authors:  M K Karczewski; K Strebel
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process.

Authors:  H Zhang; R J Pomerantz; G Dornadula; Y Sun
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Mutational analysis of human immunodeficiency virus type 1 vif gene.

Authors:  K Sakai; M Horiuchi; S Iida; T Fukumori; H Akari; A Adachi
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

8.  LuSIV cells: a reporter cell line for the detection and quantitation of a single cycle of HIV and SIV replication.

Authors:  J W Roos; M F Maughan; Z Liao; J E Hildreth; J E Clements
Journal:  Virology       Date:  2000-08-01       Impact factor: 3.616

9.  Mutational analysis of the human immunodeficiency virus type 1 Vif protein.

Authors:  J H Simon; A M Sheehy; E A Carpenter; R A Fouchier; M H Malim
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

10.  An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein.

Authors:  N Madani; D Kabat
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  176 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

3.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

Review 4.  Retroviruses under editing crossfire: a second member of the human APOBEC3 family is a Vif-blockable innate antiretroviral factor.

Authors:  Didier Trono
Journal:  EMBO Rep       Date:  2004-07       Impact factor: 8.807

5.  APOBEC3G incorporation into human immunodeficiency virus type 1 particles.

Authors:  Véronique Zennou; David Perez-Caballero; Heinrich Göttlinger; Paul D Bieniasz
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

7.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

8.  Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Authors:  Masaaki Nakashima; Hirotaka Ode; Takashi Kawamura; Shingo Kitamura; Yuriko Naganawa; Hiroaki Awazu; Shinya Tsuzuki; Kazuhiro Matsuoka; Michiko Nemoto; Atsuko Hachiya; Wataru Sugiura; Yoshiyuki Yokomaku; Nobuhisa Watanabe; Yasumasa Iwatani
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

9.  Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.

Authors:  Yunkai Yu; Zuoxiang Xiao; Elana S Ehrlich; Xianghui Yu; Xiao-Fang Yu
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

10.  CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.

Authors:  Eri Miyagi; Sandra Kao; Venkat Yedavalli; Klaus Strebel
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.